Your monthly newsletter from the |
|||||||||||||||
Table of Contents
|
|||||||||||||||
| 1) 2007 Society of Interventional Radiology (SIR) Meeting Late-Breaking Updates - Carotid Therapeutics & Stroke Prevention CASES PMS update 360-day results from the CASES PMS Trial were presented March 2, 2007 at the 2007 SIR meeting in Seattle, Washington by Dr. Barry T. Katzen, MD, FACR, FSIR, FACC. The study is a multi-center, prospective, single-arm trial of 1,493 patients evaluating the Precise nitinol stent used with the AngioGuard XP embolic protection device, both by Cordis. The primary endpoints of the study were the 30-day major adverse event rate (MAE), a composite of death, stroke and heart attack and the one-year MAE, which included the 30-day rate plus death and same-side stroke from 31 days to one year. Preliminary one-year cumulative MAE was 11.9% in the CASES-PMS trial and is similar to the 12.2% rates seen with the SAPPHIRE trial stent arm, and lower than the 20.1% for the surgical arm of the SAPPHIRE trial. The CASES-PMS Trial demonstrated similar results regardless of hospital, physician volume, or physician experience via a formal training program. These snapshot SAPPHIRE trial and CASES-PMS trial summaries can be viewed by clicking on their names. They and over 800 other trial summaries are available to subscribers to MedIntelliBase MarketTracks databases. Contact us to access specific clinical trial and registry summaries of interest to you. Imaging the Heart for Cardioembolic Stroke Prevention On March 7 at the 2007 SIR meeting Dr. John Sheehan, M.D., of Northwestern University and Northwestern Memorial Hospital in Chicago described a 106-patient retrospective study of individuals with suspected cardioembolic stroke in which a combined echocardiography (ECHO) & magnetic resonance imaging (MRI) approach was demonstrated to detect more potential causes of cardioembolic stroke than using either method alone. While each imaging technique demonstrated its strengths - ECHO (both transthoracic and transesophageal) was better at detecting shunts and bacterial growths on prosthetic valves, while MRI was better at detecting more clots - Dr. Sheehan noted that combining the two modalities improved detection and treatment of embolic source, which will likely improve secondary prevention of subsequent strokes in this high risk patient group. For more information view our MedIntelliBase Alerts "Interventional Vascular Medicine" archive abstract database. Return to Top |
|||||||||||||||
| 2) 2007 SIR Meeting Late-Breaking Updates - Endovascular Interventions Peripheral Artery Disease (PAD) and Critical Leg Ischemia (CLI) Dr. Nael Saad, M.B., B.Ch., of the University of Rochester (N.Y.) Medical Center described on March 5, 2007 that advances in devices including angioplasty balloons and stents for the treatment of PAD have allowed physicians to treat anatomic locations that were previously difficult or completely inaccessible, particularly those below the knee. Dr. Saad described a study in which 57 patients had 96 total blockages in 69 limbs at the CLI stage of PAD. 97% were treated successfully, 85% were open at 1 year, 77% were open at 2 years, and 92% avoided amputation through two years of follow-up, with additional revascularization performed when required. For more information view our MedIntelliBase Alerts "Interventional Vascular Medicine" archived abstract database. Interested in keeping up to date on this issue? Is there another area of interest where you need current, timely clinical research or technology development information? Click here to learn more about our MIB Alerts - A Better Way...to stay up to date. Return to Top |
|||||||||||||||
3) MedIntelliBase Alerts 
|
|||||||||||||||
4) Link of the Month
|
|||||||||||||||
5) Fun Fact the Month
|
|||||||||||||||
6) MedIntelliBase Custom Email Alerts now give you A Better Way ...the option of full-featured search capabilities of your:
Does this "quest for Market Intelligence" sound familiar?
MIB Alerts MedIntelliBase Custom Email Alerts are highly flexible, customized intelligent search filters powered by "Human Intelligence™" that give you convenient, timely, and tightly focused updates on new developments in your industry segment. MIB Alerts are especially suitable for busy Marketing, Business Development, and General Management executives in medical device and biotechnology companies.
Cardiac, Cardiovascular and Vascular
You get much greater value from customizable MIB Alerts than from standard market reports and search engines. You choose the exact depth and breadth of intelligence required, realizing the greatest value for your market intelligence money. Interested? Want to know more? Want a trial? Contact us for:
|
|||||||||||||||
| 7) More Information Available at www.MedIntelliBase.com You can find more in-depth information about MedIntelliBase Custom Email Alerts - visit the website at www.MedIntelliBase.com or request more information on the site. MedIntelliBase MarketTracks and Alerts will help you find the critical intelligence you need to make informed product development and business investment decisions. Contact MedIntelliBase directly... Return to Top |
|||||||||||||||
FYI:
Editor: Vicky Hunsicker Sanko The Next Phase Publishing** Market Research Analyst: Jordan Zornes The Next Phase Publishing** Phone - 425/894-4147 www.MedIntelliBase.com Toll Free - 800/390-2756 Fax - 866/381-6119 ** A division of Next Phase® Consultancy, Inc. © The Next Phase® Consultancy, Inc. 2007. All rights reserved. Return to Top |